Several studies have found that ICIs (including PD-1/PD-L1/CTLA4/LAG3) have an important function in maintaining tumor antigen tolerance but are usually hijacked by tumors to mediate their immune escape, leading to poor therapeutic outcomes in some patients with ICI therapy [56,57]. This evidence concerns the gene PDCD1 and neoplasm.